Search
Dizal Pharmaceutical Secures Accelerated FDA Approval for Self-Developed Sulvozertib®
1 week ago /
Read about 0 minute
Author：小编
Dizal Pharmaceutical's in-house developed Sulvozertib® (Sulvotinib Tablets) has garnered accelerated marketing approval from the United States Food and Drug Administration (FDA). This achievement positions Sulvozertib® as the world's pioneering domestic innovative drug tailored for adult patients suffering from locally advanced or metastatic non-small cell lung cancer who have experienced disease progression following platinum-based chemotherapy and harbor EGFR exon 20 insertion mutations.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
